Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study.

Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study. JAMA Ophthalmol. 2017 06 01; 135(6):654-656.

View in: PubMed

subject areas

Angiogenesis Inhibitors
Bevacizumab
Dose-Response Relationship, Drug
Female
Gestational Age
Humans
Infant, Newborn
Intravitreal Injections
Male
Retinopathy of Prematurity
Treatment Outcome
Vascular Endothelial Growth Factor A

authors with profiles

Raymond M Siatkowski